Solasia Pharma K.K. (Solasia), a private oncology specialized pharmaceutical company developing oncology products for Asian commercial markets, announced the filing of a New Medical Device Application for episil (SP-03) in Japan and China.

episil oral liquid represents a unique and innovative concept for local treatment of pain associated with oral mucositis (OM). Developed using the award-winning Camurus proprietary technology FluidCrystal, episil is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive film that mechanically protects the sensitized and sore mucosa of the oral cavity.

Clinically demonstrated, episil has been shown to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours. episil oral liquid is the only product for OM that is supplied as a ready-to-use, pocket-sized device helping patients maintain their quality of life while undergoing cancer therapy. episil was first launched in Europe in 2009 and is today commercially available in a number of countries, including the US where it was launched by key global pharmaceutical players. episil oral liquid is a medical device class 1 in Europe and a 510(k) registered medical device in the US.

Solasia acquired exclusive commercialization rights in Japan and China to episil from Camurus and had been developing since.

Solasia was formed in November 2006 by MPM Capital and ITOCHU Corporation to address unmet needs for important new Western oncology therapies and supportive care products throughout Asia. The company’s mission is to expedite patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries.